Pfizer reported $63.7B of revenue over the trailing twelve months, −0.21% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $63.7B (to Q2 2026). Net income: $4.33B, trailing twelve months to Q2 2026. Free cash flow: $11.0B, trailing twelve months to Q2 2026. EPS: $0.76, trailing twelve months to Q2 2026.

PFEPfizer

Healthcare

$28.27+23% 1Y

$28.27

$22.4452 weeks$29.03

PFE as reported

Pfizer reported $63.7B of revenue over the trailing twelve months, −0.21% on the year before. 9 reported series are charted on this page, each one as filed.

$63.7B

Revenue, trailing twelve months · to Q2 2026 · −0.21% against the twelve months before

Net income: $4.33B
Net income · −60% year on year · trailing twelve months to Q2 2026
Free cash flow: $11.0B
Free cash flow · −12% year on year · trailing twelve months to Q2 2026
EPS: $0.76
EPS · −60% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PFE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$63.7B	−0.21%	Q2 2026
Net income	$4.33B	−60%	Q2 2026
EPS	$0.76	−60%	Q2 2026
Gross margin	73%	n/a	Q2 2026
Net margin	7.2%	n/a	Q2 2026
ROE	8.2%	n/a	Q2 2026
ROA	3.6%	n/a	Q2 2026
Free cash flow	$11.0B	−12%	Q2 2026
P/E	37.2	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.